New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented Comparative Perspective

Neovascular age-related macular degeneration (nAMD) remains a major cause of visual morbidity worldwide, although its contribution to blindness in developed healthcare systems has declined in the era of anti-VEGF therapy. Although randomized clinical trials have consistently demonstrated meaningful...

Descrición completa

Detalles Bibliográficos

Principais autores:	Feliciana Menna, Laura De Luca, Alessandro Meduri, Antonio Baldascino, Stefano Lupo, Enzo Maria Vingolo
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2026-03-01
Series:	Biomedicines
Assuntos:	neovascular age-related macular degeneration nAMD anti-VEGF therapy faricimab aflibercept 8 mg high-dose aflibercept
Acceso en liña:	https://www.mdpi.com/2227-9059/14/4/773
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!